Fludacel — Fludarabine Phosphate
Fludarabine Phosphate is a purine-analog antimetabolite that remains a foundational treatment option for B-cell chronic lymphocytic leukemia, particularly in combination regimens where it's paired with other agents to improve overall response rates — its long track record in CLL treatment protocols means it's a consistently requested item for hematology-oncology centers building out a complete leukemia treatment formulary alongside newer targeted therapies.
- Approved indication: B-cell chronic lymphocytic leukemia (CLL)
- Mechanism: Interferes with DNA synthesis and repair in cancer cells, disrupting their ability to replicate
- Common combination: Often combined with cyclophosphamide and rituximab (FCR regimen) in fit patients for improved response rates
- Clinical role: Remains relevant even alongside newer targeted CLL therapies, particularly in markets where access to newer agents is limited by cost
Key Product Facts
50mg
Strength
Single-dose vial
Pack Size
Fludarabine Phosphate
Active Ingredient
Oncology
Category
On Request
Availability
Fludarabine Phosphate is a purine-analog antimetabolite that remains a foundational treatment option for B-cell chronic lymphocytic leukemia, particularly in combination regimens where it's paired with other agents to improve overall response rates — its long track record in CLL treatment protocols means it's a consistently requested item for hematology-oncology centers building out a complete leukemia treatment formulary alongside newer targeted therapies.
- Approved indication: B-cell chronic lymphocytic leukemia (CLL)
- Mechanism: Interferes with DNA synthesis and repair in cancer cells, disrupting their ability to replicate
- Common combination: Often combined with cyclophosphamide and rituximab (FCR regimen) in fit patients for improved response rates
- Clinical role: Remains relevant even alongside newer targeted CLL therapies, particularly in markets where access to newer agents is limited by cost
- Restrictions: Not for patients under 18, breastfeeding mothers, or those with severe renal impairment or significantly low red blood cell counts
- Vaccination: Live vaccines should be avoided during treatment given significant immunosuppression risk
- Contraception requirement: Required during treatment and for a minimum of 6 months after the final dose
- Myelosuppression: Regular blood count monitoring required — this is a dose-limiting toxicity for most patients
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| MSDS |
? Standard |
Stock status: In stock for export | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold-chain export (2–8°C)
- Coverage: Global export markets
- Tracking: Full shipment tracking included
What is Fludarabine Phosphate used for?
Treats B-cell chronic lymphocytic leukemia, often combined with other chemotherapy agents.
Get Fludarabine price from a GMP-compliant Indian supplier — how?
Send strength and destination for a verified quote.
Can it be used in kidney patients?
No, it's contraindicated in patients with severe kidney impairment.
Who supplies Fludarabine from India?
WHO-GMP certified manufacturer with full export documentation.
Can it be self-administered?
No, it must be given only under medical supervision in a hospital setting.
